These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 36543433)
1. Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction? Jia K; Ren S J Thorac Oncol; 2023 Jan; 18(1):26-28. PubMed ID: 36543433 [No Abstract] [Full Text] [Related]
2. Podcast on the Management of Adverse Events Associated with Lorlatinib. Bauer TM; Bertino EM Adv Ther; 2022 Apr; 39(4):1447-1456. PubMed ID: 35147918 [TBL] [Abstract][Full Text] [Related]
3. Lorlatinib Exposed: A Far From Optimal Dose. Strohbehn GW; Ratain MJ Clin Pharmacol Ther; 2022 Jun; 111(6):1195-1196. PubMed ID: 35394660 [No Abstract] [Full Text] [Related]
4. Lorlatinib as a treatment for ALK-positive lung cancer. Baba K; Goto Y Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143 [TBL] [Abstract][Full Text] [Related]
5. Evolocumab as treatment in lorlatinib-related hyperlipidemia. Pérez Alonso L; Cervera Calero R; Campos Fernández de Sevilla MÁ; Moreno Palanco MÁ; Gómez Cerezo JF Clin Investig Arterioscler; 2023; 35(2):88-90. PubMed ID: 36641361 [TBL] [Abstract][Full Text] [Related]
6. Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989 [TBL] [Abstract][Full Text] [Related]
9. Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. Barata F; Aguiar C; Marques TR; Marques JB; Hespanhol V Drug Saf; 2021 Aug; 44(8):825-834. PubMed ID: 34080177 [TBL] [Abstract][Full Text] [Related]
10. [Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib]. Zhou Q; Lu S; Li Y; Jia F; Li G; Hong Z; Lu Y; Fan Y; Zhou J; Liu Z; Li J; Wu YL; ; Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):555-566. PubMed ID: 36002192 [TBL] [Abstract][Full Text] [Related]
11. Lorlatinib induced proteinuria: A case report. Lee CS; Wanchoo R; Seetharamu N J Oncol Pharm Pract; 2021 Jun; 27(4):1037-1039. PubMed ID: 32996364 [TBL] [Abstract][Full Text] [Related]
12. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378 [TBL] [Abstract][Full Text] [Related]
14. Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies. Dagogo-Jack I; Abbattista A; Murphy JF; Krulewicz S; Do A; Peterson J; Lin JJ; Gainor JF; Messina R; Krueger EA; Thurm H; Yeap BY J Thorac Oncol; 2023 Jan; 18(1):67-78. PubMed ID: 36184067 [TBL] [Abstract][Full Text] [Related]
15. [Central nervous system disorders on lorlatinib: How to detect and manage in practice?]. Fallet V; Rouby P; Ahle G; Arrondeau J; Naltet C; Duflot-Boukobza A; De Crozals F; Lena H; Cortot A Bull Cancer; 2022 Apr; 109(4):477-490. PubMed ID: 35256158 [TBL] [Abstract][Full Text] [Related]
16. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Yoda S; Lin JJ; Lawrence MS; Burke BJ; Friboulet L; Langenbucher A; Dardaei L; Prutisto-Chang K; Dagogo-Jack I; Timofeevski S; Hubbeling H; Gainor JF; Ferris LA; Riley AK; Kattermann KE; Timonina D; Heist RS; Iafrate AJ; Benes CH; Lennerz JK; Mino-Kenudson M; Engelman JA; Johnson TW; Hata AN; Shaw AT Cancer Discov; 2018 Jun; 8(6):714-729. PubMed ID: 29650534 [TBL] [Abstract][Full Text] [Related]
17. Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate? Pérol M; Swalduz A J Clin Oncol; 2022 Nov; 40(31):3564-3568. PubMed ID: 35679525 [No Abstract] [Full Text] [Related]
18. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Yang J; Gong W Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349 [TBL] [Abstract][Full Text] [Related]
19. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Bauer TM; Shaw AT; Johnson ML; Navarro A; Gainor JF; Thurm H; Pithavala YK; Abbattista A; Peltz G; Felip E Target Oncol; 2020 Feb; 15(1):55-65. PubMed ID: 32060867 [TBL] [Abstract][Full Text] [Related]
20. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]